Tripeptide · Fact sheet
KPV
Also known as Lys-Pro-Val
KPV is a three-amino-acid peptide investigated for inflammatory signaling, especially in the gut. Cell and mouse results are promising research leads, but human treatment benefits and safety have not been established.
What is KPV?
KPV corresponds to the final three amino acids of alpha-melanocyte-stimulating hormone. Researchers have studied how a peptide transporter brings it into cells.
Benefits & claims
Readers look for relief from gut inflammation, skin irritation, and broad inflammatory symptoms. These claims extend beyond the human evidence available in the cited research.
What the evidence supports
- KPV reduced inflammatory signaling and disease measures in experimental colitis models.
- A mouse cancer model offers a mechanistic lead, not evidence that KPV prevents or treats human cancer.
Research areas
- Inflammatory signaling
- Experimental colitis
- Colitis-associated cancer models
Dosage & frequency
No established human regimenKPV evidence is preclinical and does not establish a human inflammatory-bowel or skin-treatment dose.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
Formulation differences
- This short alpha-MSH fragment is not an approved corticosteroid or anti-inflammatory drug.
Interactions & precautions
- Human drug-interaction studies have not established compatibility for this preclinical peptide.
What is still unresolved
- Human route, exposure, clinical efficacy, repeated-use safety, and interactions remain unestablished.
Side effects & risks
- FDA reports no identified human exposure data and insufficient safety information.
- A useful human side-effect frequency cannot be calculated from cell or mouse experiments.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Mostly animal or lab researchThe central findings come from cell systems and mouse models of colitis and inflammation-associated cancer. Human biopsy observations in a paper are not a trial of KPV treatment.
Studies
Cell experiments and two mouse colitis models.
Animal treatment results; human tissue observations do not establish treatment efficacy.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
Explore 3 sourced accounts by reported effect.
Energy: reported experiences
Slightly more energy, no broader symptom change
A commenter with self-described mast-cell symptoms reported a month of oral KPV with slightly more energy, but no change in those symptoms or other problems.
Reported use in this account
- Product
- Product described as oral KPV
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Oral
- Duration
- One month
Diagnosis, formulation and other treatments were not verified. A subjective energy change does not establish treatment of mast-cell disease.
Read the month-long commentBloating, mood swings and fatigue
A different commenter described brief symptom relief followed by worsening symptoms. Their follow-up reported bloating and mood swings with oral exposure, and marked fatigue with a different formulation.
Reported use in this account
- Product
- Products described as KPV
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Oral and sublingual in separate experiences
- Duration
- Not specified clearly
The underlying illness and product identity are unverified. The commenter offered speculative explanations that are not established by the account.
Read the adverse account and follow-upSleep: reported experiences
Better wearable sleep scores, mood and libido
After three nights with KPV, a person reported better sleep scores from a consumer ring, a more positive mood and greater libido. In a reply they also described ongoing GHK-Cu exposure.
Reported use in this account
- Product
- Product described as KPV
- Amount
- 0.25 mg
- Frequency
- Daily
- Route
- Injection; specific route not stated
- Duration
- Three days at the initial report
Other exposures described: GHK product used for about six months; High work-related stress
Three nights is a very short observation. Consumer scores are not clinical sleep measurements; ongoing GHK-Cu, expectations and ordinary variation complicate attribution.
Read the early account and repliesMood: reported experiences
Better wearable sleep scores, mood and libido
After three nights with KPV, a person reported better sleep scores from a consumer ring, a more positive mood and greater libido. In a reply they also described ongoing GHK-Cu exposure.
Reported use in this account
- Product
- Product described as KPV
- Amount
- 0.25 mg
- Frequency
- Daily
- Route
- Injection; specific route not stated
- Duration
- Three days at the initial report
Other exposures described: GHK product used for about six months; High work-related stress
Three nights is a very short observation. Consumer scores are not clinical sleep measurements; ongoing GHK-Cu, expectations and ordinary variation complicate attribution.
Read the early account and repliesBloating, mood swings and fatigue
A different commenter described brief symptom relief followed by worsening symptoms. Their follow-up reported bloating and mood swings with oral exposure, and marked fatigue with a different formulation.
Reported use in this account
- Product
- Products described as KPV
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Oral and sublingual in separate experiences
- Duration
- Not specified clearly
The underlying illness and product identity are unverified. The commenter offered speculative explanations that are not established by the account.
Read the adverse account and follow-upDigestion: reported experiences
Bloating, mood swings and fatigue
A different commenter described brief symptom relief followed by worsening symptoms. Their follow-up reported bloating and mood swings with oral exposure, and marked fatigue with a different formulation.
Reported use in this account
- Product
- Products described as KPV
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Oral and sublingual in separate experiences
- Duration
- Not specified clearly
The underlying illness and product identity are unverified. The commenter offered speculative explanations that are not established by the account.
Read the adverse account and follow-upSexual function: reported experiences
Better wearable sleep scores, mood and libido
After three nights with KPV, a person reported better sleep scores from a consumer ring, a more positive mood and greater libido. In a reply they also described ongoing GHK-Cu exposure.
Reported use in this account
- Product
- Product described as KPV
- Amount
- 0.25 mg
- Frequency
- Daily
- Route
- Injection; specific route not stated
- Duration
- Three days at the initial report
Other exposures described: GHK product used for about six months; High work-related stress
Three nights is a very short observation. Consumer scores are not clinical sleep measurements; ongoing GHK-Cu, expectations and ordinary variation complicate attribution.
Read the early account and repliesNo clear change: reported experiences
Slightly more energy, no broader symptom change
A commenter with self-described mast-cell symptoms reported a month of oral KPV with slightly more energy, but no change in those symptoms or other problems.
Reported use in this account
- Product
- Product described as oral KPV
- Amount
- Not specified clearly
- Frequency
- Not specified clearly
- Route
- Oral
- Duration
- One month
Diagnosis, formulation and other treatments were not verified. A subjective energy change does not establish treatment of mast-cell disease.
Read the month-long commentApproval status
KPV has no FDA-approved therapeutic use. The cited work is preclinical, and FDA describes a lack of human exposure data in its compounding assessment.
Preclinical evidence; no FDA approval
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Human benefits for specific gut or skin conditions
- Long-term and uncommon adverse effects
- Interactions and reliable product exposure
Summary
KPV belongs in the preclinical research category; an anti-inflammatory mechanism is not an established treatment benefit.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- fdaFDA: safety concerns for selected bulk substances
Ingredient-specific safety findings; compounding review is not drug approval.
- pubmedPepT1-mediated KPV uptake and intestinal inflammation
Cell experiments and two mouse colitis models.
- pubmedKPV in a murine colitis-associated cancer model
Animal treatment results; human tissue observations do not establish treatment efficacy.